• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    5/1/26 4:15:28 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    false 0001844392 0001844392 2026-04-29 2026-04-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 29, 2026

     

    MARPAI, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware   001-40904   86-1916231
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    615 Channelside Drive, Suite 207    
    Tampa, Florida   33602
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (855) 389-7330

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A Common Stock, par value $0.0001 per share   MRAI   OTCQX Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    As previously disclosed, on February 13, 2026, Marpai, Inc. (the “Company”) issued a promissory note (the “Note”) in the principal amount of $410,000 to Damien Lamendola, the Company’s Chief Executive Officer (the “Holder”), with an interest rate of 12% per annum and that matures on April 11, 2026.

     

    In addition, and as previously disclosed, on March 9, 2026, the Company issued a second promissory note (the “Second Note”) in the principal amount of $250,000 to the Holder with an interest rate of 12% per annum and that matures on May 10, 2026.

     

    On April 29, 2026, the Company entered into an Amendment Agreement (the “Amendment Agreement”) with the Holder pursuant to which the maturity date of the Note and the Second Note for the outstanding principal and interest was extended from April 11, 2026 and May 10, 2026, respectively, to September 1, 2026. All other terms and conditions of the Note and the Second Note remain unchanged.

     

    The foregoing does not purport to be a complete description of the Amendment Agreement, and such description is qualified in its entirety by reference to the full text of such document, which is attached as Exhibit 10.1 to this Current Report on Form 8-K (this “Form 8-K”) and is incorporated by reference herein.

      

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
      Description
    10.1   Form of Promissory Note Amendment Agreement, dated as of April 29, 2026, between the Company and Damien Lamendola.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      MARPAI, INC.
         
    Date: May 1, 2026 By: /s/ Damien Lamendola
        Name: Damien Lamendola
        Title: Chief Executive Officer

     

    2

     

    Get the next $MRAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    6/2/26 5:01:11 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Eitan Yaron bought $2,700 worth of shares (10,000 units at $0.27), increasing direct ownership by 0.92% to 1,099,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    5/22/26 4:02:13 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Marpai Inc. Announces Unprecedented Growth with 192,000 New Estimated Member Lives Across TPA and MarpaiRx PBM Platforms; Expects to Achieve Positive Cash Flow and EBITDA Beginning August 2026

    TAMPA, Fla., May 26, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration ("TPA"), and Pharmacy Benefit Management ("PBM") services, today announced a historic expansion of its business book. Following a series of newly secured commitments and confirmed new business across its Third-Party Administrator (TPA) and MarpaiRx Pharmacy Benefit Management (PBM) platforms, the Company estimates a total increase of 192,000 member lives scheduled to roll out between August 2026 and January 2027.This influx represents a nearly six-fold increase in the Company's current member lives, potentially transforming

    5/26/26 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

    Strategic Investments in Operations and Technology Fuel Platform for Accelerated Growth and Aim of Second-Half 2026 ProfitabilityTAMPA, Fla., May 15, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management ("PBM") services, announced the financial results for the first quarter 2026.Marpai's first quarter 2026 results reflect the Company's continued execution of its operational transformation designed to position the business for profitability and growth. The Company has nearly completed the migration of its IT and claims processing to a single, unified cloud-bas

    5/15/26 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai, Inc. Announces Significant New Business Wins across TPA and MarpaiRx; Solidifies Forecast for Profitability

    TAMPA, Fla., May 11, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration ("TPA"), and Pharmacy Benefit Management ("PBM") services, today announced several significant new business wins across its core TPA and MarpaiRx divisions. These new client wins, representing a diverse range of self-insured employer groups, are expected to be primary drivers in the Company's path toward achieving sustained profitability.Pursuant to the newly secured contracts, Marpai is expected to provide comprehensive TPA services and integrated pharmacy benefit management services through MarpaiRx, reflect the growing de

    5/11/26 10:22:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron returned 50,000 shares to the company and was granted 175,000 shares, decreasing direct ownership by 4% to 1,224,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    6/2/26 5:02:06 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    6/2/26 5:01:11 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv returned 50,000 shares to the company and was granted 125,000 shares, decreasing direct ownership by 8% to 613,667 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    6/2/26 5:00:16 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    SEC Filings

    View All

    SEC Form 10-Q filed by Marpai Inc.

    10-Q - Marpai, Inc. (0001844392) (Filer)

    5/15/26 4:16:21 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    5/1/26 4:15:28 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-K filed by Marpai Inc.

    10-K - Marpai, Inc. (0001844392) (Filer)

    3/25/26 4:44:45 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

    Strategic Investments in Operations and Technology Fuel Platform for Accelerated Growth and Aim of Second-Half 2026 ProfitabilityTAMPA, Fla., May 15, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management ("PBM") services, announced the financial results for the first quarter 2026.Marpai's first quarter 2026 results reflect the Company's continued execution of its operational transformation designed to position the business for profitability and growth. The Company has nearly completed the migration of its IT and claims processing to a single, unified cloud-bas

    5/15/26 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

    Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

    5/13/25 9:01:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Financials

    Live finance-specific insights

    View All

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS

    TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, November 13 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q3 2025. The Company will report its third quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q3 Financial Results Conference Call Date: November 13, 2025 Time: 8:30 a.m. Eastern Time Call: US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:  https://app.webinar.net/934VMynbB6a Follow us on X.com and LinkedIn You may str

    11/6/25 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut 70% as Turnaround Gains Traction TAMPA, Fla., Aug. 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy. The Company delivered substantial quarterly year-over-year improvements across key financial metrics: Operating expenses down 70%, saving $9.9 millionOperating loss reduced by 71% to $3.6 million, an $8.7 million improvementNet loss reduced by 66% to $4.4 million, als

    8/13/25 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    9/4/24 7:55:41 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    5/29/24 4:01:02 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care